(2R)-2-hydroxy-4,4-dimethylpentanoic acid | 114990-91-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2R)-2-hydroxy-4,4-dimethylpentanoic acid
• 英文别名: 4,4-dimethyl-2(R)-hydroxypentanoic acid；(R)-2-Hydroxy-4,4-dimethyl-pentanoic acid；(R)-2-hydroxy-4,4-dimethylpentanoic acid
• CAS: 114990-91-9
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: OPBFFNZNNJKRCS-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2R)-2-hydroxy-4,4-dimethylpentanoic acid 在 吡啶 、 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 (1S,5R)-N-[[5-chloro-2-(tetrazol-1-yl)phenyl]methyl]-2-[(2R)-2-hydroxy-4,4-dimethylpentanoyl]-2-azabicyclo[3.1.0]hexane-1-carboxamide
  参考文献：
  名称：

  Discovery of AZD8165 – a clinical candidate from a novel series of neutral thrombin inhibitors

  摘要：

  一系列新型中性凝血酶抑制剂已经开发出来，采用基于对接实验、性质计算和预测的选择过程。

  DOI：

  10.1039/c5md00479a
• 作为产物：
  描述：

  3-叔丁基-D-Β-丙氨酸/(R)-3-氨基-4,4-二甲基戊酸 生成 (2R)-2-hydroxy-4,4-dimethylpentanoic acid
  参考文献：
  名称：

  Thrombin inhibitors

  摘要：

  该发明的化合物在抑制凝血酶和相关的血栓闭塞方面具有用途，具有以下结构：或其药用盐，例如1-(3(S)-环丙基-2(R)-羟基丁酰)氮杂环丙烷-2(S)-N-(2-氨甲基-5-氯苄基)羧酰胺，和1-(3-环丙基-3-甲基-2(R)-羟基丁酰)氮杂环丙烷-2(S)-N-(2-氨甲基-5-氯苄基)羧酰胺。

  公开号：

  US06528503B2

文献信息

• [EN] BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY<br/>[FR] COMPOSÉS HÉTÉROARYLE BICYCLIQUES UTILES EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION PAR-2
  申请人：VERTEX PHARMA

  公开号：WO2016154075A1

  公开（公告）日：2016-09-29

  The compounds of formula I, wherein the variables are as defined herein, and pharmaceutically acceptable salts thereof are useful as inhibitors of the PAR-2 signaling pathway. The compounds of formula I and pharmaceutically acceptable compositions comprising such compounds can be employed for treating various diseases, disorders, and conditions.

  式I的化合物，其中变量如本文所定义，并且其药学上可接受的盐可用作PAR-2信号通路的抑制剂。式I的化合物和包含这些化合物的药学上可接受的组合物可用于治疗各种疾病、疾病和症状。
• [EN] QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS<br/>[FR] QUINAZOLINES UTILES EN TANT QUE MODULATEURS DE CANAUX IONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2006028904A1

  公开（公告）日：2006-03-16

  The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及作为电压门控钠通道抑制剂的化合物。该发明还提供了包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• Thrombin inhibitors
  申请人：——

  公开号：US20030013700A1

  公开（公告）日：2003-01-16

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: 1 or a pharmaceutically acceptable salt thereof, e.g. 1-(3(S)-Cyclopropyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide, and 1-(3-Cyclopropyl-3-methyl-2(R)-hydroxybutanoyl)azetidine-2(S)-N-(2-aminomethyl-5-chlorobenzyl)carboxamide.

  该发明的化合物可用于抑制凝血酶和相关的血栓闭塞，具有以下结构：1或其药学上可接受的盐，例如1-(3(S)-环丙基-2(R)-羟基丁酰)氮杂环丙烷-2(S)-N-(2-氨基甲基-5-氯苯甲基)羧酰胺，和1-(3-环丙基-3-甲基-2(R)-羟基丁酰)氮杂环丙烷-2(S)-N-(2-氨基甲基-5-氯苯甲基)羧酰胺。
• [EN] NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS<br/>[FR] PROMEDICAMENTS DE DIARYL-2-(5H)-FURANONES EN TANT QU'INHIBITEURS DE LA CYCLO-OXYGENASE-2 LIBERANT DE L'OXYDE NITRIQUE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2004011421A1

  公开（公告）日：2004-02-05

  The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.

  该发明涵盖了一种新颖的Formula I化合物，这些化合物是一种二苯基-2-(5H)呋喃酮的一氧化氮释放前药，用于治疗环氧合酶-2介导的疾病。该发明还涵盖了某些用于治疗环氧合酶-2介导疾病的药物组合和方法，包括使用Formula I化合物。上述化合物可作为低剂量阿司匹林的联合治疗，用于治疗慢性环氧合酶-2介导的疾病或症状，同时减少血栓性心血管事件的风险。
• Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
  申请人：Berthelette Carl

  公开号：US20050261245A1

  公开（公告）日：2005-11-24

  The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.

  本发明涵盖了化合物I的新型化合物，其为二芳基-2-(5H)呋喃酮的一氧化氮释放前药，可用于治疗环氧合酶-2介导的疾病。本发明还涵盖了某些药物组合和方法，用于治疗环氧合酶-2介导的疾病，包括使用化合物I。上述化合物可与低剂量阿司匹林组合治疗慢性环氧合酶-2介导的疾病或病症，同时降低血栓性心血管事件的风险。